Cybin Inc. (d/b/a Helus Pharma) closed an underwritten offering of 10,309,280 common shares at US$4.85 per share, raising approximately US$50 million in gross proceeds. The net proceeds will be used to advance the HLP003, HLP004, and HLP005 programs, including Phase 3 clinical development for HLP003. The company is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.
